Medical Information | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
We summarize key results from the phase II ALLG study of ibrutinib + R-mini-CHOP in older patients with newly diagnosed DLBCL.
Acalabrutinib plus chemoimmunotherapy has received FDA approval for patients with previously untreated MCL, following positive results from the phase III ECHO trial.
NCCN Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma (DLBCL) were updated to include a ctDNA-MRD testing recommendation for B-cell lymphoma.
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
During the Lymphoma Hub Steering Committee meeting, Martin Dreyling, Ludwig-Maximilians-Universität, Munich, DE, chaired a discussion on, How to treat MCL that is refractory to BTK…
We summarize results from the TRIANGLE trial evaluating the role of auto-HSCT in ibrutinib-containing first-line treatment in younger patients with MCL.
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
During the Lymphoma Hub Steering Committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on, How to treat older…
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease